Breedlove Robert Charles
Principal Accounting Officer
Breedlove Robert Charles has filed 7 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.
On the most recent filing, Breedlove Robert Charles is listed as Principal Accounting Officer at Phathom Pharmaceuticals, Inc. Inside the rolling window, Breedlove Robert Charles reported no open-market purchases and 1 open-market sale totaling $7K in PHAT.
Companies traded
Other insiders at PHAT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 5, 2025 | PHAT | Sale | $6K |
Frequently asked questions
How many SEC Form 4 filings has Breedlove Robert Charles made?
Breedlove Robert Charles has filed 7 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Breedlove Robert Charles trade?
Breedlove Robert Charles has filed SEC Form 4 disclosures for 1 company, including PHAT.
When was Breedlove Robert Charles's most recent SEC Form 4 filing?
Breedlove Robert Charles's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.
What is Breedlove Robert Charles's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Breedlove Robert Charles is listed as Principal Accounting Officer.
What is Breedlove Robert Charles's total buy and sell value in the current window?
Inside the rolling retention window, Breedlove Robert Charles bought $0 and sold $7K based on SEC Form 4 filings.
What was Breedlove Robert Charles's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 524 PHAT shares on 2025-11-03, worth $7K, per SEC Form 4 filings.